Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 2
2011 6
2012 6
2013 1
2016 2
2017 1
2020 1
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T, O'Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, Patel D, von Rosenstiel P, von Hehn C, Salloway S, Hock C, Nitsch RM, Haeberlein SB, Sandrock A, Singhal P. Chen T, et al. Among authors: rajagovindan r. Alzheimers Dement. 2024 Apr 3. doi: 10.1002/alz.13755. Online ahead of print. Alzheimers Dement. 2024. PMID: 38567735
TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease.
Shulman M, Kong J, O'Gorman J, Ratti E, Rajagovindan R, Viollet L, Huang E, Sharma S, Racine AM, Czerkowicz J, Graham D, Li Y, Hering H, Haeberlein SB. Shulman M, et al. Among authors: rajagovindan r. Nat Aging. 2023 Dec;3(12):1591-1601. doi: 10.1038/s43587-023-00523-w. Epub 2023 Nov 27. Nat Aging. 2023. PMID: 38012285 Free PMC article. Clinical Trial.
Correction to: Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
Muralidharan KK, Kowalski KG, Tong X, Haeberlein SB, Rajagovindan R, Nestoro I. Muralidharan KK, et al. Among authors: rajagovindan r. J Pharmacokinet Pharmacodyn. 2023 Apr;50(2):145. doi: 10.1007/s10928-023-09852-0. J Pharmacokinet Pharmacodyn. 2023. PMID: 36870006 No abstract available.
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab.
Nisenbaum L, Martone R, Chen T, Rajagovindan R, Dent G, Beaver J, Rubel C, Racine A, He P, Harrison K, Dean R, Vandijck M, Haeberlein SB. Nisenbaum L, et al. Among authors: rajagovindan r. Alzheimers Dement. 2023 Aug;19(8):3379-3388. doi: 10.1002/alz.12919. Epub 2023 Feb 16. Alzheimers Dement. 2023. PMID: 36795603 Clinical Trial.
Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
Muralidharan KK, Kowalski KG, Tong X, Haeberlein SB, Rajagovindan R, Nestorov I. Muralidharan KK, et al. Among authors: rajagovindan r. J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):45-62. doi: 10.1007/s10928-022-09839-3. Epub 2023 Jan 4. J Pharmacokinet Pharmacodyn. 2023. PMID: 36600109 Clinical Trial.
Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
Lin L, Hua F, Salinas C, Young C, Bussiere T, Apgar JF, Burke JM, Kandadi Muralidharan K, Rajagovindan R, Nestorov I. Lin L, et al. Among authors: rajagovindan r. CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):362-372. doi: 10.1002/psp4.12759. Epub 2022 Feb 3. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35029320 Free PMC article.
Pharmacological modulation of brain activity in a preclinical model of osteoarthritis.
Upadhyay J, Baker SJ, Rajagovindan R, Hart M, Chandran P, Hooker BA, Cassar S, Mikusa JP, Tovcimak A, Wald MJ, Joshi SK, Bannon A, Medema JK, Beaver J, Honore P, Kamath RV, Fox GB, Day M. Upadhyay J, et al. Among authors: rajagovindan r. Neuroimage. 2013 Jan 1;64:341-55. doi: 10.1016/j.neuroimage.2012.08.084. Epub 2012 Sep 7. Neuroimage. 2013. PMID: 22982372
19 results